Wall Street brokerages expect Lipocine Inc (NASDAQ:LPCN) to post earnings per share (EPS) of ($0.25) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Lipocine’s earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.22). Lipocine reported earnings per share of ($0.22) in the same quarter last year, which would suggest a negative year-over-year growth rate of 13.6%. The firm is expected to issue its next earnings report on Wednesday, November 14th.
On average, analysts expect that Lipocine will report full-year earnings of ($0.80) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.62). For the next year, analysts forecast that the company will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.98) to $0.24. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Lipocine.
Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.10.
Lipocine stock opened at $1.52 on Tuesday. Lipocine has a 1-year low of $1.03 and a 1-year high of $4.38. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.89 and a quick ratio of 8.89. The company has a market capitalization of $33.49 million, a PE ratio of -1.45 and a beta of 0.49.
Lipocine Company Profile
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Featured Article: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.